XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022   71,047      
Beginning balance at Dec. 31, 2022 $ 309,965 $ 71 $ 635,668 $ (2,688) $ (323,086)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares)   139      
Issuance of common stock upon exercise of stock options 3,125   3,125    
Issuance of common stock upon vesting of restricted stock units (in shares)   358      
Issuance of common stock upon vesting of restricted stock units 1 $ 1      
Stock-based compensation 51,516   51,516    
Other comprehensive income (loss) 1,727     1,727  
Net loss (27,248)       (27,248)
Ending balance (in shares) at Mar. 31, 2023   71,544      
Ending balance at Mar. 31, 2023 339,086 $ 72 690,309 (961) (350,334)
Beginning balance (in shares) at Dec. 31, 2023   73,317      
Beginning balance at Dec. 31, 2023 538,085 $ 73 942,280 582 (404,850)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of new capped calls associated with the 2029 convertible senior notes (93,438)   (93,438)    
Partial termination of existing capped calls associated with the 2025 convertible senior notes 539   539    
Issuance of common stock upon exercise of stock options (in shares)   14      
Issuance of common stock upon exercise of stock options 386   386    
Issuance of common stock upon vesting of restricted stock units (in shares)   518      
Issuance of common stock upon vesting of restricted stock units 1 $ 1      
Stock-based compensation 45,987   45,987    
Other comprehensive income (loss) (885)     (885)  
Net loss (7,077)       (7,077)
Ending balance (in shares) at Mar. 31, 2024   73,849      
Ending balance at Mar. 31, 2024 $ 483,598 $ 74 $ 895,754 $ (303) $ (411,927)